IRIS
PANICHELLA, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.789
AS - Asia 3.772
EU - Europa 3.492
SA - Sud America 760
AF - Africa 96
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.918
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.537
IT - Italia 1.440
SG - Singapore 1.358
CN - Cina 957
RU - Federazione Russa 859
BR - Brasile 591
VN - Vietnam 460
BD - Bangladesh 330
HK - Hong Kong 207
GB - Regno Unito 171
NL - Olanda 165
DE - Germania 163
IE - Irlanda 159
CA - Canada 142
FR - Francia 117
FI - Finlandia 111
IN - India 83
TR - Turchia 76
SE - Svezia 68
MX - Messico 64
PL - Polonia 64
AR - Argentina 63
PK - Pakistan 46
ES - Italia 36
ID - Indonesia 36
IQ - Iraq 36
EC - Ecuador 34
ZA - Sudafrica 34
IL - Israele 32
JP - Giappone 30
AT - Austria 27
CO - Colombia 24
UZ - Uzbekistan 21
UA - Ucraina 20
MA - Marocco 17
CH - Svizzera 15
EG - Egitto 14
LT - Lituania 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 12
BE - Belgio 12
CL - Cile 12
PH - Filippine 11
SA - Arabia Saudita 10
MY - Malesia 9
RO - Romania 9
HN - Honduras 8
KE - Kenya 8
PY - Paraguay 8
KR - Corea 7
NP - Nepal 7
PE - Perù 7
TN - Tunisia 7
AU - Australia 6
GT - Guatemala 6
PT - Portogallo 6
DZ - Algeria 5
JO - Giordania 5
KZ - Kazakistan 5
OM - Oman 5
BY - Bielorussia 4
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
GR - Grecia 4
JM - Giamaica 4
NI - Nicaragua 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
CG - Congo 3
CZ - Repubblica Ceca 3
KW - Kuwait 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
HR - Croazia 2
IR - Iran 2
KH - Cambogia 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
PS - Palestinian Territory 2
QA - Qatar 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AD - Andorra 1
AG - Antigua e Barbuda 1
BB - Barbados 1
BH - Bahrain 1
CU - Cuba 1
CV - Capo Verde 1
DM - Dominica 1
EE - Estonia 1
Totale 11.896
Salva come PNG Salva come JPEG
Città #
Dallas 822
Singapore 744
San Jose 406
Ashburn 398
Beijing 331
Hong Kong 196
Moscow 159
Milan 157
Dublin 156
Los Angeles 154
Ho Chi Minh City 153
New York 126
Rome 112
Council Bluffs 103
Hanoi 103
Santa Clara 81
Helsinki 74
Pisa 66
São Paulo 65
The Dalles 65
Chandler 60
Hefei 54
Lauterbourg 54
Warsaw 54
Florence 53
Munich 52
Istanbul 47
Montreal 44
London 40
Orem 40
Amsterdam 37
Bologna 37
Naples 36
Da Nang 34
Frankfurt am Main 34
Mexico City 34
Chicago 33
Genoa 33
Buffalo 32
Boardman 31
Turin 30
Beauharnois 29
Brooklyn 27
Lucca 27
Tokyo 27
Atlanta 26
Poplar 26
Rio de Janeiro 26
Stockholm 25
Tel Aviv 25
Boston 24
Lappeenranta 24
Johannesburg 23
Nuremberg 23
Toronto 23
Chennai 22
Denver 22
Brescia 20
Seattle 20
Livorno 19
Figino 18
Mumbai 17
Tashkent 17
Belo Horizonte 15
Haiphong 15
Lahore 15
Manchester 15
Phoenix 15
Washington 15
Guayaquil 14
Palermo 14
Biên Hòa 13
Houston 13
Shenzhen 13
Assago 12
Bari 12
Charlotte 12
Columbus 12
Curitiba 12
Paris 12
Quito 12
Turku 12
Verona 12
Dhaka 11
Querétaro 11
Redondo Beach 11
Baghdad 10
Cambridge 10
Guangzhou 10
Ottawa 10
San Mateo 10
Vienna 10
Brasília 9
Cagliari 9
Hangzhou 9
Portsmouth 9
San Francisco 9
Suzhou 9
Zhengzhou 9
Ankara 8
Totale 6.279
Salva come PNG Salva come JPEG
Nome #
Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation 609
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 440
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 329
The Fondazione Toscana Gabriele Monasterio app: a digital health system to improve wellbeing of inpatients with heart or lung disease 327
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 313
Eligibility for vericiguat in a real‐world, contemporary heart failure population 303
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis 295
Screening the health status of people working in a university 294
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 288
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 285
Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population 272
RNA-targeting and gene editing therapies for transthyretin amyloidosis 263
Assessing cardiac mechanics through left ventricular haemodynamic forces 245
Valvular heart disease in patients with cardiac amyloidosis 238
Role of Imaging in Cardiomyopathies 237
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 236
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 235
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 218
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 214
Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review 214
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 211
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis 211
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 209
Cardiac Amyloidosis: How Its Epidemiology is Changing 208
Subclinical cardiac damage in cancer patients before chemotherapy 207
The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population 202
Sex-related differences in ventricular remodeling after myocardial infarction 202
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 200
Bridging Atrial and Ventricular Failure Through Biomarkers 200
High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis 195
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 192
Sex differences in transthyretin cardiac amyloidosis 184
Pathophysiology of Cardiac Amyloidosis 180
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 180
Gamma-glutamyltransferase independently predicts mortality and hospitalization for heart failure in cardiac transthyretin amyloidosis 180
Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity 178
Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review 177
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 176
The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers 176
Echocardiographic Estimate of Pulmonary Capillary Wedge Pressure Improves Outcome Prediction in Heart Failure Patients with Reduced and Mildly Reduced Ejection Fraction 175
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 164
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 163
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin 160
Heart failure with preserved ejection fraction risk after aortic coarctation surgery: The hidden threat 160
CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis 156
Dissecting the heart failure phenotype through phenomics 144
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 142
Metabolomics to predict heart failure development: A new frontier? 141
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 124
Pirfenidone as a novel cardiac protective treatment 122
Insulin‐like growth factor binding protein‐7 in heart failure: The challenge of moving from risk prediction to a biomarker‐guided management 121
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond 118
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up 116
Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It? 112
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy 110
Changes in CMR-derived ventricular strain, fibrosis progression and outcomes in hypertrophic cardiomyopathy 70
Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It? 47
The evolving role of metabolic and bariatric surgery in contemporary clinical practice 34
PAWP vs LVEDP During Invasive Cardiopulmonary Exercise Testing: In Search of the Holy Grail of a Hemodynamic Truth in Heart Failure. 33
null 29
Therapy of amyloidosis: stabilizers and silencers 16
Event rates in major Phase 3 heart failure trials over the last 20 years 14
Totale 11.994
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.111
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.111
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202266 0 0 0 5 7 7 10 17 7 6 2 5
2022/2023367 5 28 10 21 44 40 14 47 109 10 27 12
2023/2024333 13 11 63 36 7 25 27 13 15 26 28 69
2024/20252.806 71 68 134 108 184 154 383 539 286 175 378 326
2025/20268.205 441 1.077 771 1.145 801 561 747 477 549 544 588 504
2026/2027217 217 0 0 0 0 0 0 0 0 0 0 0
Totale 11.994